The estrogen blockers market comprises antiestrogenic agents that are used to block the effects of estrogen in various therapeutic applications such as breast cancer therapy and contraception. Estrogen blockers help in managing breast cancer risk by inhibiting the action of estrogen, which is one of the leading causes of breast cancer. Selective estrogen receptor modulators (SERMs) such as tamoxifen and raloxifene are the most commonly used estrogen blockers for breast cancer treatment and prevention. The rising prevalence of breast cancer worldwide along with growing awareness about various preventive measures including estrogen blocker therapy is fueling market growth. The Global estrogen blockers market is estimated to be valued at US$ 17.31 Mn in 2024 and is expected to exhibit a CAGR of 5.9% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the estrogen blockers market are Central Drug House, Croda International Plc., Emery Oleochemicals, Glentham Life Sciences Limited, Haihang Industry, Kunshan Odowell Co., Ltd, Matrica S.p.A, OQ Chemicals GmbH, Tokyo Chemical Industry Co., Ltd., and Zhengzhou Yibang Industry & Commerce Co., Ltd. Central Drug House and Croda International Plc captured significant market share in 2021.
There is high growth prospect in Asia Pacific and Latin America owing to increasing disposable income and health awareness. Leading players are focusing on establishing manufacturing and distribution facilities in developing countries through partnerships with local players.
Key opportunities in the market include development of novel formulations with added advantages such as higher efficacy and longer duration of action. Leading players are investing heavily in R&D to introduce advanced estrogen blockers with improved safety profiles and better thermoregulatory properties.
Globally, companies are expanding their footprint through strategic collaborations with regional healthcare providers as well as generic manufacturers. Major players are also undertaking mergers and acquisitions to strengthen their product portfolios and geographic presence across emerging markets.
Market drivers:
Increasing global burden of breast cancer: According to WHO, breast cancer is the most common cancer among women worldwide with an estimated 2.3 million new cases and 685,000 deaths in 2020.
Rising awareness: Growing public awareness about various preventive measures including estrogen blocking therapy is fueling the adoption of estrogen blockers.
Market restraints:
Stringent regulations: Estrogen Blockers Market Demand are subject to strict quality and safety regulations due to their anti-carcinogenic effects. This increases R&D and compliance costs for manufacturers.
Side effects: Adverse effects of estrogen blockers such as thromboembolic disorders limits their uptake especially for preventive use.
Segment Analysis
The Estrogen Blockers market can be segmented into type and application. Based on type, the aromatase inhibitors segment dominates the market as they work by inhibiting the enzyme aromatase, which converts androgens into estrogens. Aromatase inhibitors are highly prescribed for breast cancer treatment. By application, the pharmaceutical segment holds the largest share as estrogen blockers are majorly used in hormone replacement therapy and breast cancer treatment.
Global Analysis
Regionally, North America holds the largest share in the estrogen blockers market owing to high awareness among people regarding cancer treatment and supportive government initiatives. Furthermore, presence of prominent players and established healthcare infrastructure drive the market in the region. Europe is the second largest market due to increasing incidence of breast cancer and technological advancements in drug development. Meanwhile, Asia Pacific is expected to witness the fastest growth during the forecast period. This is attributed to growing healthcare expenditure, rising cases of breast cancer, and improving healthcare facilities. Improving economic conditions leading to better access to advanced treatment options boost the market growth in developing countries of Asia Pacific.
Comments
0 comment